Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 24, 2026

Geely Technology Ecosystem on Full Display and Debut of China’s First Purpose-Built Robotaxi at Auto China 2026

View original at finance.yahoo.com
Geely Technology Ecosystem on Full Display and Debut of China’s First Purpose-Built Robotaxi at Auto China 2026 BEIJING, April 24, 2026 (GLOBE NEWSWIRE) -- Geely Auto Group attended Auto China 2026 (Beijing Auto Show) for the first time directly as an exhibitor and showcased the group’s full technology ecosystem…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EVA Cab is China's first purpose-built Robotaxi prototype

    60% confidence
  • The Quantum-Level AI Electronic and Electrical Architecture is the world's first

    60% confidence
  • Geely is the first global automaker to obtain the ISO 8800 AI Safety certification

    60% confidence
  • The 2160-line digital LiDAR system is the world's first

    60% confidence
  • SOVD technology is industry-first Service-Oriented Vehicle-Cloud Integrated Diagnostics

    60% confidence
  • EVA Cab demonstrates Geely's full entry into the Full-Domain AI 2.0 era

    60% confidence
  • EVA Cab features the industry's first mass-production-ready L4-level assisted driving software solution

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
Geely Technology Ecosystem on Full Display and Debut of China’s First Purpose-Built Robotaxi at Auto China 2026 — Source | Via News | Via News